CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And Investors
gece33/E+ via Getty Images
I. Introduction
CEL-SCI (NYSE: CVM) is a Virginia-based biotech company aimed at fighting squamous cell head and neck cancer. It just announced successful Phase III clinical trial results and it intends to seek FDA approval in…
